Loading...

PODCAST

Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit

health & fitness medicine

All Episodes

19:04

Pancreatic Cancer Management - Partners in Practice...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/06

Join us in this insightful episode of our new series, Partners in Practice. We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer.In this episode, we were joined by Dr. Timothy Brown, a GI medical oncologist from UT Southwestern, and Ms. Heather Klein, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX, NALIRIFOX, gemcitabine with nab-paclitaxel, and the

en

24:26

Treatment Algorithm of Late Relapsed/Refractory...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/08/03

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression.Key topics included: The current treatment algorithms for late relapse refractory

en

22:53

Treatment Algorithm of Early Relapsed/Refractory...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/30

In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.Key topics discussed included: The current standard of care for frontline multiple myeloma, including quadruplet therapy and

en

16:55

ENDURANCE Trial - Time-limited Lenalidomide...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/28

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in multiple myeloma treatment, focusing on the practice changing ENDURANCE trial. Joined by esteemed guests Dr. Shaji Kumar and Dr. Vincent Rajkumar from Mayo Clinic, they discussed the new time limited approach being the standard of care for maintenance therapy in standard-risk multiple myeloma patients.Key topics include: Overview of the ENDURANCE trial and its implications for clinical

en

22:47

Managing Toxicities of CAR-T in Multiple Myeloma (MM)...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/23

In this informative episode we dived into the world of CAR T-cell therapies for multiple myeloma. In this ToxCheck episode, we focused on the available CAR-T options, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and discussed their side effects, management strategies, and the importance of patient education.We were joined by myeloma specialists Caitlin Costello, MD, from UC San Diego Health, and Joshua Richter, MD, from Mount Sinai, who shared their

en

23:56

Challenging Cases in Relapsed/Refractory Multiple...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/20

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of treating multiple myeloma, focusing on two challenging cases from the community. Joined by experts Marco Davila, MD PhD, from Roswell Park Comprehensive Cancer Center and Krina Patel, MD MSc, from MD Anderson Cancer Center, they discuss the nuances of treatment options for patients experiencing disease relapse post-transplant and disease progression while on maintenance therapy. Key topics included: The

en

22:22

Treatment Algorithm of Smoldering Myeloma & Newly...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/16

Join the Oncology Brothers, in this insightful episode as they dive deep into the treatment algorithms for newly diagnosed multiple myeloma and smoldering myeloma. Featuring Gurbakhash Kaur, MD, a myeloma specialist from the Mount Sinai Hospital, the discussion covered the latest advancements in treatment options, including the recent approval of daratumumab for high-risk smoldering myeloma and the evolving landscape of frontline therapies. In this episode, you'll learn about: The definition of

en

15:42

EHA2026 Leukemia Highlights: OPTI-AML, KOMET-007, SENTRY

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/13

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the latest highlights from the EHA 2026 conference, focusing on groundbreaking studies in the leukemia space. Join us as we welcome Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center to discuss three pivotal studies: OPTI-AML: explored the findings on the use of venetoclax in combination with azacitidine for newly diagnosed AML patients, comparing 14-day versus 28-day treatment regimens and their impact on

en

23:57

Challenging Cases in Diffuse Large B-cell Lymphoma...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/09

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely? Key

en

18:04

EHA2026 Lymphoma Highlights: frontMIND, POLAR-BEAR,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/06

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma. Join us as we dived into four pivotal studies: frontMIND: We explored the efficacy of tafasitamab plus lenalidomide with R-CHOP compared to R-CHOP alone in frontline treatment for diffuse large B-cell lymphoma

en

20:39

Sacituzumab +/- Pembrolizumab FDA Approval in Triple...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/04

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Dr. Sara Tolaney, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed the exciting developments in breast cancer treatment, with ASCENT-03 and ASCENT-04 trials. Key topics covered in this episode include: Overview of the recent FDA approvals for antibody-drug conjugates

en

31:25

ASCO 2026 Breast Highlights: OPTIMA, lidERA,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/07/02

In this ASCO 2026 Highlights discussion we dived into the latest advancements in breast cancer space. In this episode, we welcomed back Dr. Hope Rugo to discuss key studies that are shaping the future of breast cancer treatment. Episode Highlights: OPTIMA: Discover how the Prosigna genomic assay could change the approach to adjuvant chemotherapy in hormone receptor-positive breast cancer. lidERA Update: Learn about the promising results of giredestrant, an oral SERD, and its potential role in

en

24:19

EHA2026 Multiple Myeloma Highlights: CEPHEUS,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/29

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026. Join us as we dived into: The CEPHEUS study update, reaffirming the standard of care with quadruple therapy upfront, specifically D-VRd Insights on the efficacy of teclistamab in early relapse refractory settings, including updates from

en

36:30

Evolving Treatment Landscape of Multiple Myeloma:...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/26

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents. Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of

en

22:05

Challenging Cases - Treatment of Renal Cell Carcinoma...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/25

Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals. We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best

en

33:32

ASCO 2026 GU Highlights & FDA Approvals with Drs....

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/22

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast. In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS: trial comparing ADT monotherapy to apalutamide plus ADT in

en

23:56

To hold or NOT to hold Systemic Therapy with...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/18

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Nina Sanford, a GI radiation oncologist from UT Southwestern, to discuss a critical topic in cancer treatment: when to hold and not to hold systemic therapy during radiation and for how long.Join us as we explore: The framework for balancing systemic therapy with different types of radiation, including SBRT, palliative, and conventional radiation. Insights on managing cytotoxic chemotherapy, immunotherapy,

en

23:30

ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/15

Welcome back to the Oncology Brothers podcast! In this episode we are joined by Dr. Neena Vijayvergia from Fox Chase Cancer Center to discuss the latest highlights from ASCO 2026, focusing on gastrointestinal (GI) studies.We discussed key studies: EMERALD-3 in HCC: Exploring the findings on combining TACE with Durvalumab and Tremelimumab, and the implications for patient outcomes. FIGHT-302 in Cholangiocarcinoma: The potential of FGFR inhibitors in frontline settings and the challenges of

en

22:48

RASolute 302 Pancreatic Cancer Study with...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/11

In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute. We discussed: The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients. The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug,

en

25:29

ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs....

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/06/08

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the key highlights from ASCO 2026, focusing on groundbreaking studies in head and neck cancer and sarcoma. Join us as we discuss: Nasopharyngeal Carcinoma: comparing carboplatin and cisplatin in induction and concurrent chemoradiation therapy. Can we extrapolate these findings to other head and neck cancers? Amivantamab in Head and Neck Cancer: Insights from the OrigAMI4 study, showcasing the efficacy of amivantamab in

en

290 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Healthy Chat

DR ALI BANIHAMOUR

Dingue ‐ RTS

RTS - Radio Télévision Suisse

Optimal Health Daily - Fitness and Nutrition

Optimal Living Daily | Dr. Neal Malik

Muscles by Brussels Radio

Dani Taylor